Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
This WP specifically aims to elucidate the effects of IEK on hypoxic tolerance and the development and severity of AMS symptoms, blood and tissue oxygenation status, as well as sleep quality during an episode of acute exposure to severe hypoxia.
Acute altitude exposure impairs exercise tolerance and performance, decreases the rate of maximal oxygen uptake (V̇O2max), cognitive function and sleep quality, and often also induces symptoms of acute mountain sickness (AMS). Previous studies have clearly indicated that ketone bodies exert a neuroprotective effect under hypoxic-ischemic conditions as well as improve hypoxic tolerance in rodents. In support of these earlier observations, recent pilot experiments in young volunteers in our laboratory provide proof of concept that IEK can attenuate oxygen desaturation during exercise in hypoxia. Therefore, given that impaired exercise tolerance in hypoxia is primarily due to impaired oxidative energy production in active tissues (brain and muscle), we hypothesize that IEK can increase blood and tissue (muscle and brain) oxygenation status in hypoxia and thereby enhance global hypoxic tolerance, as well as improve exercise tolerance and endurance exercise performance.
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Ketone group | Experimental | Ketone esters will be provided |
|
| Placebo group | Placebo Comparator | Ketone placebo will be provided |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Ketone ester | Dietary Supplement | A total of 240g ketone ester supplementation will be provided in one of the 28h experimental sessions in order to establish intermittent exogenous ketosis. Sucralose (5% w/w) is added to the ketone ester (R)-3-hydroxybutyl (R)-3-hydroxybutyrate |
| Measure | Description | Time Frame |
|---|---|---|
| Change in incidence of acute mountain sickness symptoms | Scored by Lake Louise Scoring system | Hour 0 - Hour 4 - Hour 10 - Hour 24 - Hour 28 |
| Change in oxygenation status of brain, blood, muscle | Measured by NIRS, pulse oximetry, blood samples | Hour 1 - Hour 4 - Hour 10 - Hour 24 - Hour 28 |
| Change in cerebral blood flow | Measured using duplex ultrasound | Hour 1 - Hour 4 - Hour 10 - Hour 24 - Hour 28 |
| Time in hypoxia | Total time that subjects were able to comply to the experimental protocol and supplementation protocol | From start of hypoxic exposure until subjects are too sick to comply to (supplementation) protocol or until end of protocol, up to 29 hours |
| Measure | Description | Time Frame |
|---|---|---|
| Sleep quality | Measured using polysomnography | Throughout the entire duration of the night, up to 9 hours after individual bedtime |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Chiel Poffé, Dr. | KU Leuven | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| KU Leuven | Leuven | Vlaams-Brabant | 3000 | Belgium |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D007662 | Ketosis |
| D000860 | Hypoxia |
| D000532 | Altitude Sickness |
| D060825 | Cognitive Dysfunction |
| ID | Term |
|---|---|
| D000138 | Acidosis |
| D000137 | Acid-Base Imbalance |
| D008659 | Metabolic Diseases |
| D009750 | Nutritional and Metabolic Diseases |
Not provided
Not provided
| ID | Term |
|---|---|
| C524675 | formic acid 4-(3-oxobutyl)phenyl ester |
Not provided
Not provided
Not provided
1 session with ketone ester supplementation and 1 session with taste and viscosity matched placebo
Not provided
Not provided
Not provided
| Placebo | Dietary Supplement | Water, 5% sucralose (w/w), octaacetate (1 mM) |
|
| D012818 |
| Signs and Symptoms, Respiratory |
| D012816 | Signs and Symptoms |
| D013568 | Pathological Conditions, Signs and Symptoms |
| D012120 | Respiration Disorders |
| D012140 | Respiratory Tract Diseases |
| D003072 | Cognition Disorders |
| D019965 | Neurocognitive Disorders |
| D001523 | Mental Disorders |